3 completed, 3 terminated, 2 recruiting, 1 active not recruiting. 11 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 11 | Completed 3, Terminated 3, Recruiting 2, Active not recruiting 1, Not yet recruiting 1, Withdrawn 1 |
| Phase 2 | 4 | Completed 2, Terminated 2 |
Follow Deafness: new trials by email Literature Review of Deafness trials Research Report on Deafness
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome N-acetylcysteine amide, Placebo - Retinitis Pigmentosa (RP), Usher Syndrome | Phase 3 | Not yet recruiting | Nacuity Pharmaceuticals, Inc. | 80 | 2026-12-01 | 2026-07-01 |
| A 24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome Placebo, NPI-001 - Retinitis Pigmentosa (RP), Usher Syndrome | Phase 3 | Recruiting | Nacuity Pharmaceuticals, Inc. | 80 | 2026-10-23 | 2026-11-10 |
| Oral N-acetylcysteine for Retinitis Pigmentosa N-acetylcysteine, Placebo - Retinitis Pigmentosa | Phase 3 | Active not recruiting | Johns Hopkins University | 485 | 2023-10-11 | 2026-06-15 |
| Gene Therapy Trial for Otoferlin Gene-mediated Hearing Loss AAVAnc80-hOTOF via Akouos Delivery Device, AAVAnc80-hOTOF via Akouos Delivery Device and Precision Delivery Mechanism - Sensorineural Hearing Loss, Bilateral | Phase 3 | Recruiting | Eli Lilly and Company | 48 | 2023-09-15 | 2026-09-29 |
| Study to Evaluate the Efficacy Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene With Early to Moderate Vision Loss (Celeste) QR-421a, Sham-procedure - Retinitis Pigmentosa, Usher Syndrome Type 2 | Phase 2 / Phase 3 | Terminated | Laboratoires Thea | 5 | 2021-12-15 | 2024-08-07 |
| Study to Evaluate the Efficacy Safety and Tolerability of Ultevursen in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene (Sirius) Ultevursen, Sham-procedure - Retinitis Pigmentosa, Usher Syndrome Type 2 | Phase 2 / Phase 3 | Terminated | Laboratoires Thea | 7 | 2021-12-08 | 2024-07-12 |
| Efficacy and Safety of AM-111 as Acute Sudden Sensorineural Hearing Loss Treatment AM-111 0.4 mg/ml, AM-111 0.8 mg/ml, Placebo - Hearing Loss, Idiopathic Sudden Sensorineural | Phase 3 | Terminated | Auris Medical, Inc. | 56 | 2016-06-01 | 2020-08-07 |
| AM-111 in the Treatment of Acute Inner Ear Hearing Loss Placebo, AM-111 0.4 mg/ml, AM-111 0.8 mg/ml - Hearing Loss | Phase 3 | Completed | Auris Medical AG | 256 | 2015-11-01 | 2023-09-14 |
| Comparison of the Bilateral Sequential and Simultaneous Cochlear Implantation in the Deaf Children bilateral cochlear Implantation in sequential, bilateral cochlear Implantation in simultaneous - Deafness | Phase 3 | Withdrawn | Assistance Publique - Hôpitaux de Paris | 2012-01-01 | 2012-11-19 | |
| Multicenter Trial Assessing an Innovative VAS of Pain Among Deaf People pictorial VAS, usual VAS - Deafness, Visual Analog Pain Scale | Phase 2 / Phase 3 | Completed | University Hospital, Grenoble | 289 | 2011-06-01 | 2013-07-23 |
| Protective Effect of N-acetylcysteine Against From Ototoxicity N-acetylcysteine - Hearing Loss, Extreme | Phase 2 / Phase 3 | Completed | TC Erciyes University | 60 | 2010-06-01 | 2011-11-16 |
Retinitis Pigmentosa (5) · Usher Syndromes (5) · Hearing Loss (3) · Hearing Loss, Sensorineural (3) · Ear Diseases (2) · Eye Abnormalities (2) · Eye Diseases (2) · Eye Diseases, Hereditary (2) · Hearing Disorders (2) · Hearing Loss, Unilateral (2) · Otorhinolaryngologic Diseases (2) · Retinal Diseases (2) · Sensation Disorders (2) · Signs and Symptoms (2)
Pathological Conditions, Signs and Symptoms (11) · Nervous System Diseases (10) · Neurologic Manifestations (10) · Ear Diseases (9) · Hearing Disorders (9) · Otorhinolaryngologic Diseases (9) · Sensation Disorders (9) · Signs and Symptoms (9) · Hearing Loss (8) · Abnormalities, Multiple (5) · Blindness (5) · Congenital Abnormalities (5) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (5) · Deaf-Blind Disorders (5)
Acetylcysteine (2) · D-JNKI-1 (2) · Intravitreal Injections (2) · N-Acetylcysteinamide (1)
Laboratoires Thea (2) · Nacuity Pharmaceuticals, Inc. (2) · Assistance Publique - Hôpitaux de Paris (1) · Auris Medical AG (1) · Auris Medical, Inc. (1) · Eli Lilly and Company (1) · Johns Hopkins University (1) · TC Erciyes University (1) · University Hospital, Grenoble (1)
United States (6) · United Kingdom (4) · Canada (3) · Germany (2) · Netherlands (2) · Austria (1) · Bulgaria (1) · France (1) · South Korea (1) · Switzerland (1) · Taiwan (1) · Turkey (Türkiye) (1)
Benoit Mongourdin, PH (1) · Ismail Kocyigit, MD (1) · Nathalie Loundon, MD, MD-PhD (1) · Peter A Campochiaro, MD (1) · Sarah Neuhaus, D.O. (1) · Thomas Meier (1) · Xiangrong Kong (1)
PMID 25073872, PMID 41282901, PMID 42635483
1UG1EY033293 (1)